BioNTech SE (NASDAQ:BNTX) Short Interest Up 9.4% in December

BioNTech SE (NASDAQ:BNTX) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 2,550,000 shares, an increase of 9.4% from the December 15th total of 2,330,000 shares. Based on an average daily volume of 806,600 shares, the days-to-cover ratio is currently 3.2 days.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BNTX. Planning Capital Management Corp lifted its position in shares of BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after buying an additional 450 shares during the last quarter. Blue Trust Inc. lifted its holdings in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after purchasing an additional 388 shares in the last quarter. GAMMA Investing LLC lifted its holdings in BioNTech by 21.7% during the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after purchasing an additional 111 shares in the last quarter. Clear Harbor Asset Management LLC purchased a new stake in BioNTech during the 3rd quarter worth about $210,000. Finally, Probity Advisors Inc. purchased a new stake in BioNTech during the 3rd quarter worth about $216,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

BNTX stock traded down $0.83 during midday trading on Friday, hitting $111.93. The company’s stock had a trading volume of 458,339 shares, compared to its average volume of 565,513. The stock’s 50-day moving average price is $114.69 and its 200 day moving average price is $104.59. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter in the prior year, the firm earned $0.73 EPS. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. As a group, research analysts predict that BioNTech will post -3.71 earnings per share for the current year.

Analyst Ratings Changes

BNTX has been the subject of several recent research reports. JPMorgan Chase & Co. decreased their price objective on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a report on Tuesday, November 26th. BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $90.00 to $137.00 in a report on Friday, November 8th. HSBC boosted their price objective on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a report on Monday, October 7th. Finally, HC Wainwright restated a “buy” rating and set a $150.00 price objective on shares of BioNTech in a report on Monday, November 18th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and an average price target of $142.72.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.